Some cardiovascular complications in patients with chronic kidney disease and end-stage renal disease may be caused by structurally and functionally modified lipoproteins. Redox status (advanced oxidation protein products [AOPPs]), prooxidant–antioxidant balance, total protein sulfhydryl (SH-groups), and paraoxonase 1 (PON1) activity were assessed in 77 renal patients and 20 controls. Lipoproteins were isolated using ultracentrifugation. PON1, PON3, and pentraxin-3 concentration were determined by enzyme-linked immunosorbent assay (ELISA). Dyslipidemia-Oxy-Inflammation (DOI) score was calculated as a sum of dyslipidemia, oxidative stress, and inflammation scores. The dyslipidemia score (P < .001), oxy score (P < .01), inflammation score (P < .001), and the DOI score (P < .001) were higher in patient groups compared with controls. The very-low-density lipoprotein (VLDL) fraction contained the highest amount of AOPP (P < .001) compared with other lipoprotein fractions in all groups. The low-density lipoprotein (LDL) fraction contained elevated AOPP in all groups compared with the high-density lipoprotein (HDL) fraction (P < .001). Significant positive correlation was observed between AOPP in LDL fraction and DOI score (ρ = 0.510, P < .01). Dyslipidemia, oxidative stress, and inflammation play an interactive role in renal disease and are mutually associated with redox status in VLDL, LDL, and HDL lipoproteins in plasma of renal patients.
GansevoortRTCorrea-RotterRHemmelgarnBR. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9829):339–52.
2.
MikolasevicIŽutelijaMMavrinacVOrlicL. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.
3.
Kotur-StevuljevicJSimic-OgrizovicSDopsajV. A hazardous link between malnutrition, inflammation, and oxidative stress in renal patients. Clin Biochem. 2012;45(15):1202–5.
4.
ChistiakovDAMelnichenkoAAOrekhovANBobryshevYV. Paraoxonase and atherosclerosis-related cardiovascular diseases. Biochimie. 2017;132:19–27.
5.
GugliucciAKotaniKKimuraS. Paraoxonase 1 in chronic kidney failure. J Lipids. 2012;2012:726048.
6.
AbbasMAMohamedNYAbd El-FattahWM. Plasma pentraxin-3 level as a biomarker in patients with chronic kidney disease and its association with cardiovascular complications. Life Sci J. 2013;10:2949–58.
7.
UngurianuAMarginăDGrădinaruD. Lipoprotein redox status evaluation as a marker of cardiovascular disease risk in patients with inflammatory disease. Molec Med Rep. 2017;15(1):256–62.
8.
RoccoMVBernsJS. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kid Dis. 2012;60(5):850–86.
9.
FukuyamaNHommaKWakanaN. Validation of the Friedewald equation for evaluation of plasma LDL-cholesterol. J Clin Biochem Nutr. 2008;43(1):1–5.
10.
RichterRJJarvikGPFurlongCE. Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol. 2010;660:29–35.
11.
Kotur-StevuljevicJBogavac-StanojevicNJelic-IvanovicZ. Oxidative stress and paraoxonase 1 status in acute ischemic stroke patients. Atherosclerosis. 2015;241(1):192–8.
12.
Witko-SarsatVFriedlanderMCapeillère-BlandinC. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49(5):1304–13.
13.
AlamdariDHPaletasKPegiouTSarigianniMBefaniCKoliakosG. A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem. 2007;40(3-4):248–54.
14.
VegliaFCighettiGDe FranceschiM. Age- and gender-related oxidative status determined in healthy subjects by means of OXY-SCORE, a potential new comprehensive index. Biomarkers. 2006;11(6):562–73.
15.
McPhersonPYoungIMcKibbenB. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J Lipids. 2007;48(1):86–95.
16.
SuttnarJMásováLDyrJE. Influence of citrate and EDTA anticoagulants on plasma malondialdehyde concentrations estimated by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;751(1):193–7.
17.
HosmerDWJrLemeshowS. Applied Logistic Regression. New York: John Wiley and Sons; 2004:373.
FlorensNCalzadaCLyaskoEJuillardLSoulageCO. Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins. Toxins. 2016;8(12).pii:E376.
20.
HolzerMSchilcherGCurcicS. Dialysis modalities and HDL composition and function. J Am Soc Nephrol. 2015;26(9):2267–76.
21.
MastorikouMMacknessBLiuYMacknessM. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med. 2008;25(9):1049–55.
22.
RosenblatMKarryRAviramM. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein deficient serum: relevance to diabetes. Atherosclerosis. 2006;187(1):74–81.
23.
SoranHSchofieldJDDurringtonPN. Antioxidant properties of HDL. Front Pharmacol. 2015;6:222.
24.
GugliucciAMehlhaffKKinugasaE. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta. 2007;377(1-2):213–20.
25.
ReddySTWadleighDJGrijalvaV. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21(4):542–7.
26.
SchweikertEMDevarajanAWitteI. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ. 2012;19(9):1549–60.
Meenakshi SundaramSPNagarajanSManjula DeviAJ. Chronic kidney disease—effect of oxidative stress. Chinese J Biol. 2014;2014:1–6.
29.
AsmatUAbadKIsmailK. Diabetes mellitus and oxidative stress—a concise review. Saudi Pharm J. 2016;24(5):547–53.
30.
GwinnerWGröneHJ. Role of reactive oxygen species in glomerulonephritis. Nephrol Dial Transplant. 2000;15(8):1127–32.
31.
MikrutKKupszJKozlikJKraussHPruszynska-OszmałekEGibas-DornaM. Angiotensin-converting enzyme inhibitors reduce oxidative stress intensity in hyperglicemic conditions in rats independently from bradykinin receptor inhibitors. Croat Med J. 2016;57(4):371–80.
32.
KuchtaAPacanisAKortas-StempakB. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res. 2011;34(1):12–9.
33.
YilmazMISonmezAOrtizA. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol. 2011;6(4):785–92.
34.
VekicJZeljkovicABogavac-StanojevicN. Cox proportional hazard model analysis of survival in end-stage renal disease patients with small-sized high-density lipoprotein particles. Clin Biochem. 2011;44(8-9):635–41.
35.
SamouilidouEKostopoulosVLiaouriA. Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease. Ren Fail. 2016;38(10):1601–6.
36.
HolzerMBirner-GruenbergerRStojakovicT. Uremia alters HDL composition and function. J Am Soc Nephrol. 2011;22(9):1631–41.
37.
PoirierBMichelOBazinRBariétyJChevalierJMyaraI. Conjugated dienes: a critical trait of lipoprotein oxidizability in renal fibrosis. Nephrol Dial Transplant. 2001;16(8):1598–606.
38.
HafezMMAl-ShabanahOAAl-HarbiNO. Association between paraoxonases gene expression and oxidative stress in hepatotoxicity induced by CCl4. Oxid Med Cell Longev. 2014;2014:893212.
39.
MikhailidisDPElisafMRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–2.
